Literature DB >> 21777275

Update of fecal markers of inflammation in inflammatory bowel disease.

Thomas A Judd1, Andrew S Day, Daniel A Lemberg, Dan Turner, Steven T Leach.   

Abstract

The diagnosis, prognosis, and assessment of disease activity of inflammatory bowel disease (IBD) require investigating clinical, radiological, and histological criteria, as well as serum inflammatory markers. However, a range of fecal inflammatory markers now appears to have the potential to greatly assist in these processes. Calprotectin, a prominent neutrophil protein, was identified two decades ago as a potentially revolutionary marker for IBD. Following this discovery, numerous additional markers, including S100A12, lactoferrin, and M2-pyruvate kinase, have also been suggested as novel markers of IBD. In the present study, we provide an up-to-date review of fecal markers of IBD, and further, provide a novel analysis of each of these fecal markers in severe ulcerative colitis and compare their expression pattern in contrast to calprotectin.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21777275     DOI: 10.1111/j.1440-1746.2011.06846.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  30 in total

1.  Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

Authors:  Aleksandra M Urbanska; Emmanouil D Karagiannis; Gonzalo Guajardo; Robert S Langer; Daniel G Anderson
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

2.  Fecal M2-PK in children with Crohn's disease: a preliminary report.

Authors:  A S Day; T Judd; D A Lemberg; S T Leach
Journal:  Dig Dis Sci       Date:  2012-06-27       Impact factor: 3.199

Review 3.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

4.  Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Phillip I Tarr; David B Haslam
Journal:  J Pediatr       Date:  2013-09-04       Impact factor: 4.406

5.  Assessing disease activity in patients with ulcerative colitis.

Authors:  Alissa Walsh; Simon Travis
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-11

Review 6.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 7.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 8.  Refractory inflammatory bowel disease-could it be an irritable bowel?

Authors:  Jie Meng; Anurag Agrawal; Peter J Whorwell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-09-11       Impact factor: 46.802

Review 9.  Functions of S100 proteins.

Authors:  R Donato; B R Cannon; G Sorci; F Riuzzi; K Hsu; D J Weber; C L Geczy
Journal:  Curr Mol Med       Date:  2013-01       Impact factor: 2.222

10.  Noninvasive measurement of intestinal inflammation after burn injury.

Authors:  Michael Sigman; Peggie Conrad; Juan L Rendon; Suhail Akhtar; Joshua Eberhardt; Richard L Gamelli; Mashkoor A Choudhry
Journal:  J Burn Care Res       Date:  2013 Nov-Dec       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.